BRAF V600E

BRAF codon 600 point mutation p.V600E detected by sequencing, PCR or mutation-specific immunohistochemistry; used as a predictive marker for BRAF/MEK inhibitor therapy across melanoma, thyroid, colorectal, lung and other cancers.

CI-BIO-00000018BRAF graph →NCIt C98342 Tumor-agnostic · 4 approval rows

Also calledp.V600E · BRAF V600E-mutant · c.1799T>A

Tissue-agnostic indications

Approval rows flagged tumor-agnostic (4)

Dabrafenib US FDA · Mar 16, 2023 · drug + indication textRegulatory approved
Dabrafenib US FDA · May 29, 2013 · drug + indication textRegulatory approved
Trametinib US FDA · Mar 16, 2023 · drug + indication textRegulatory approved
Trametinib US FDA · May 29, 2013 · drug + indication textRegulatory approved

The flag is the source's (openFDA label text), never inferred; the full indication text of each row is in the Approvals section below.

Derived

Associated cancers (24)

Cancers mapped in ACCEPTED CIViC predictive, prognostic or diagnostic items whose variant (molecular markers) or gene (gene-level markers) is in this biomarker's scope. Counts by type and native level; each row links to the cancer's evidence tab.

Computedrule biomarker-links-v1

Cancer	Items	Predictive	Prognostic	Diagnostic	Levels A / B / C / D / E
Malignant Colorectal Neoplasm	37	31	6	—	1 / 21 / 6 / 8 / 1
Melanoma	31	29	2	—	0 / 19 / 2 / 10 / 0
Thyroid Gland Papillary Carcinoma	12	3	8

Derived

Drugs with predictive evidence (29)

Therapies named in in-scope PREDICTIVE CIViC items, plus targets of PREDICTS_RESPONSE_TO knowledge edges from in-scope variants. Sensitivity and resistance are counted separately and never merged into a verdict.

Computedrule biomarker-links-v1

Drug	CIViC items	Sensitivity	Resistance	Best level	Edges (S / R)	Cancer context
VemurafenibSmall Molecule	45	36	9	A	34 / 9	Childhood Pilocytic Astrocytoma, Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor +12
DabrafenibSmall Molecule	22	19	3	A	18 / 4	Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor, Intrahepatic Cholangiocarcinoma +8
TrametinibSmall Molecule	20	19	1	A	18 / 0	Cholangiocarcinoma, Cutaneous Melanoma, Digestive System Neuroendocrine Tumor, Intrahepatic Cholangiocarcinoma +8
CetuximabMonoclonal Antibody	12	6	6	A	6 / 5	Malignant Colorectal Neoplasm
PanitumumabMonoclonal Antibody	9	6	3	B	4 / 2	Cholangiocarcinoma, Malignant Colorectal Neoplasm
IrinotecanSmall Molecule	6	3	3	B	3 / 3	Cholangiocarcinoma, Malignant Colorectal Neoplasm
SelumetinibSmall Molecule	4	3	1	B	1 / 1	Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
CobimetinibSmall Molecule	3	3	—	B	3 / 0	Malignant Colorectal Neoplasm, Malignant Neoplasm, Melanoma
EncorafenibSmall Molecule	3	3	—	A	3 / 0	Malignant Colorectal Neoplasm
BevacizumabMonoclonal Antibody	2	1	1	B	1 / 1	Malignant Colorectal Neoplasm
BinimetinibSmall Molecule	2	2	—	B	2 / 0	Malignant Colorectal Neoplasm
CapecitabineSmall Molecule	2	1	1	B	1 / 1	Malignant Colorectal Neoplasm
DactolisibSmall Molecule	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
OxaliplatinSmall Molecule	2	—	2	B	0 / 2	Malignant Colorectal Neoplasm
PLX4720	2	2	—	D	2 / 0	Malignant Colorectal Neoplasm, Melanoma
UprosertibSmall Molecule	2	2	—	D	2 / 0	Melanoma
ErlotinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
FOLFOX-4 Regimen	1	—	1	B	0 / 1	Malignant Colorectal Neoplasm
GDC-0879Small Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
GefitinibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
JQEZ5	1	1	—	D	1 / 0	Melanoma
Nutlin-3Small Molecule	1	1	—	D	1 / 0	Melanoma
PertuzumabMonoclonal Antibody	1	1	—	C	1 / 0	Thyroid Gland Anaplastic Carcinoma
PictilisibSmall Molecule	1	1	—	C	1 / 0	Melanoma
Pictilisib Bismesylate	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
SorafenibSmall Molecule	1	1	—	D	1 / 0	Malignant Colorectal Neoplasm
TovorafenibSmall Molecule	1	1	—	A	1 / 0	Childhood Low Grade Glioma
MEK Inhibitor RO4987655	1	—	1	B	—	Melanoma
MirdametinibSmall Molecule	1	—	1	D	—	Melanoma

Curatedcivic items and knowledge edges as curated at the source.

Curated evidence

Predictive evidence items (92)

ACCEPTED CIViC predictive items in scope, grouped by molecular profile and therapy with native level, direction and cancer context. 50 per page.

civicCuratedShowing 1–50 of 92 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
BRAF V600E + BRAF Fusion1
Tovorafenib	Childhood Low Grade Glioma	Predictive	A	Supports Sensitivity Response	5	accepted	EID12016 In this ongoing phase 2 trial (FIREFLY-1), 76 patients, aged 6 months to 25 years, with pediatric low-grade glioma harbouring BRAF alterations (BRAF fusions or BRAF V600E mutations) were treated with … (full text at CIViC) PMID 37978284 · Kilburn et al., 2024 · Open in CIViC	civic
BRAF V600E45
Vemurafenib	Childhood Pilocytic Astrocytoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID3777 In a case report, a 28 month old patient with a cervicomedullary low grade glioma compatible with pilocytic astrocytoma which was resected had a second lesion consistent with a ganglioglioma 3 years l… (full text at CIViC) PMID 25524464 · del Bufalo et al., 2014 · Open in CIViC	civic
Dabrafenib + TrametinibCombination	Cholangiocarcinoma	Predictive	C	Supports Sensitivity Response	3	accepted	EID5902 Chemotherapy-refractory, metastatic cholangiocarcinoma with CNS involvement and a BRAF V600E mutation had a partial response at 8 weeks to dabrafenib and trametinib combination with complete radiologi… (full text at CIViC) PMID 28480077 · Kocsis et al., 2017 · Open in CIViC	civic
Irinotecan + Panitumumab + VemurafenibCombination	Cholangiocarcinoma
BRAF K601E + BRAF V600E1
Cobimetinib + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	B	Supports Sensitivity Response	3	accepted	EID11670 This clinical study was conducted with 30 patients with colorectal cancer harboring BRAF V600E (n = 29) or BRAF K601E (n=1) mutations, treated with a combination of cobimetinib and vemurafenib. Of the… (full text at CIViC) PMID 36409971 · Klute et al., 2022 · Open in CIViC	civic
BRAF Amplification + BRAF V600E1
Selumetinib	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	E	Supports Resistance	4	accepted	EID92 COLO201 and COLO206F cells harboring BRAF V600E mutations were cloned to be MEK inhibitor (AZD6244 [selumetinib]) resistant. The mechanism of this resistance was shown to be amplification of the BRAF … (full text at CIViC) PMID 21098728 · Corcoran et al., 2010 · Open in CIViC	civic
ARAF S490T + BRAF V600EBRAF ARAF1
Cetuximab + Irinotecan + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	1	accepted	EID1905 Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient h… (full text at CIViC) PMID 27729313 · Hong et al., 2016 · Open in CIViC	civic
BRAF V600E + GNAS R201CBRAF GNAS1
Cetuximab + Irinotecan + VemurafenibCombination	Malignant Colorectal NeoplasmCURATED_BROADER	Predictive	C	Supports Resistance	2	accepted	EID1906 Phase 1b study of vemurafenib, cetuximab and irinotecan in 19 BRAF V600E mutant colorectal cancer patients. cfDNA panel sequencing was performed in 10 patients after disease progression. One patient a… (full text at CIViC) PMID 27729313 · Hong et al., 2016 · Open in CIViC	civic

Regulatory

Approvals mentioning the linked drugs (364)

Approval records of the derived drug set, plus records whose indication text names this biomarker. Each record names its authority, jurisdiction, indication text and status — a drug approved in one jurisdiction for one indication is not 'approved' in general, and an approval listed here is not necessarily restricted to this biomarker.

Computedrule biomarker-links-v1

openfdaRegulatory14 approval records from 3 sources (hover a row badge for its dataset) · authority, jurisdiction and indication text as published.

Drug	Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
Trametinib	US FDA	Malignant Colorectal Neoplasm	Limitations of Use : MEKINIST is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to BRAF inhibition.	approved	May 29, 2013	openfda
Trametinib	US FDA	Thyroid Gland Anaplastic Carcinoma	the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (ATC) with BRAF V600E mutation, as detected by an FDA-approved test, and with no satisfactory locoregional treatment options.	approved	May 29, 2013	openfda
Trametinib	US FDA	Lung Non-Small Cell Carcinoma	the treatment of patients with metastatic non-small cell lung cancer (NSCLC) with BRAF V600E mutation as detected by an FDA-approved test.	approved	May 29, 2013	openfda

1 record matched on indication text only (drug not in the derived set). Health Canada DIN rows carry no indication text and only match by drug.

Clinical trials

Active trials (473)

Trials with an active ClinicalTrials.gov status, an intervention mapped to a derived drug and a condition mapped to an associated cancer. 247 recruiting · 84 active phase 3 · 2,296 in any status. Most recently updated first, 50 per page.

Computedrule biomarker-links-v1

clinicaltrialsPublishedShowing 251–300 of 473 active studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03947385	Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions	recruiting	Phase 1 / Phase 2	336	IDEAYA BiosciencesINDUSTRY	3	Jun 8, 2026	clinicaltrials
NCT04074096	Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis(BEPCOME-MB)	active not recruiting	Phase 2	10	UNICANCEROTHER	1	Jun 5, 2026	clinicaltrials
NCT00492999	Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver	active not recruiting	Phase 2	64	Memorial Sloan Kettering Cancer CenterOTHER	1	Jun 3, 2026	clinicaltrials
NCT04796012	VITAS: Atezolizumab in Combination With Chemotherapy for Pediatric Relapsed/Refractory Solid Tumors	recruiting	Phase 1 / Phase 2	23	University of Texas Southwestern Medical CenterOTHER	1	Jun 2, 2026	clinicaltrials
NCT05445778	Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer(GLORIOSA)	active not recruiting	Phase 3	520	AbbVieINDUSTRY	22	Jun 2, 2026	clinicaltrials
NCT06917079	BBO-11818 in Adult Subjects With KRAS Mutant Cancer	recruiting	Phase 1	665	TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)INDUSTRY	2	Jun 2, 2026	clinicaltrials
NCT07621497	FOLFOX8 Versus mFOLFOX6 With Bevacizumab or Cetuximab for First-Line Unresectable Metastatic Colorectal Cancer (Phase II)	not yet recruiting	Phase 2	229	Sun Yat-sen UniversityOTHER	1	Jun 2, 2026	clinicaltrials
NCT03213002	Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM(CAPTEM)	recruiting	Phase 1 / Phase 2	67	Northwell HealthOTHER	1	Jun 1, 2026	clinicaltrials
NCT05039801	IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors	recruiting	Phase 1	54	M.D. Anderson Cancer CenterOTHER	1	Jun 1, 2026	clinicaltrials
NCT01167712	Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer	active not recruiting	Phase 3	692	National Cancer Institute (NCI)NIH	3	May 29, 2026	clinicaltrials
NCT04956640	Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)	active not recruiting	Phase 1 / Phase 2	540	Eli Lilly and CompanyINDUSTRY	6	May 29, 2026	clinicaltrials
NCT06465563	SHR-8068 in Combination With Adebrelimab, Bevacizumab, and Platinum-Based Chemotherapy as First-line Treatment in Patients With Advanced Biliary Tract Cancer	active not recruiting	Phase 2	93	Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY	1	May 29, 2026	clinicaltrials
NCT07223047	A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies	recruiting	Phase 1 / Phase 2	252	Bristol-Myers SquibbINDUSTRY	3	May 28, 2026	clinicaltrials
NCT05910827	A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers	recruiting	Phase 1 / Phase 2	398	Hummingbird BioscienceINDUSTRY	5	May 27, 2026	clinicaltrials
NCT05800587	Dose Attenuated Chemotherapy in Compromised Patients With Lung Cancer	recruiting	Phase 2	280	Fox Chase Cancer CenterOTHER	1	May 22, 2026	clinicaltrials
NCT06006273	A Phase Ib Trial of Eribulin in Combination With Irinotecan and Temozolamide in Children With Relapsed or Refractory Solid Tumors	recruiting	Phase 1	48	M.D. Anderson Cancer CenterOTHER	1	May 20, 2026	clinicaltrials
NCT04901702	Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma	recruiting	Phase 1 / Phase 2	90	St. Jude Children's Research HospitalOTHER	2	May 19, 2026	clinicaltrials
NCT05468359	Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients	recruiting	Phase 1 / Phase 2	64	St. Jude Children's Research HospitalOTHER	1	May 19, 2026	clinicaltrials
NCT07359456	Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases(COLIBRI-GI)	not yet recruiting	Phase 2	130	UNICANCEROTHER	1	May 19, 2026	clinicaltrials
NCT07595276	Comparing Efficacy and Safety of Enlituo® Versus Erbitux® Plus FOLFOX in Locally Advanced/Metastatic Colorectal Cancer With RAS/BRAF Wild-type and MSS/pMMR Status.	not yet recruiting	Phase 3	608	Taizhou Mabtech Pharmaceutical Co.,LtdINDUSTRY	1	May 19, 2026	clinicaltrials
NCT06083844	Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy	recruiting	Phase 2	20	M.D. Anderson Cancer CenterOTHER	1	May 18, 2026	clinicaltrials
NCT07094204	A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors	recruiting	Phase 1	364	Astellas Pharma IncINDUSTRY	4	May 18, 2026	clinicaltrials
NCT07331155	A Phase II Clinical Study of LBL-024 Combination Therapy in Patients With Advanced Solid Tumour[Substudy 03(ESCC)]	recruiting	Phase 2	110	Nanjing Leads Biolabs Co.,LtdINDUSTRY	1	May 18, 2026	clinicaltrials
NCT05566795	DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2)	active not recruiting	Phase 3	418	Day One Biopharmaceuticals, Inc.INDUSTRY	30	May 14, 2026	clinicaltrials
NCT07432295	Givastomig Combined With Nivolumab and Chemotherapy in Adults With CLDN18.2 Positive Metastatic Gastric Cancer (GIVA-2)	recruiting	Phase 2	180	I-Mab Biopharma US LimitedINDUSTRY	3	May 14, 2026	clinicaltrials
NCT07365592	Neoadjuvant Chemotherapy, Anti-PD-1 Antibody and Sitagliptin for Locally Advanced pMMR CRC(Neo-CD)	recruiting	Phase 1 / Phase 2	138	Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER	1	May 13, 2026	clinicaltrials
NCT07390383	A Phase II Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumour[Substudy 04]	recruiting	Phase 2	110	Nanjing Leads Biolabs Co.,LtdINDUSTRY	1	May 13, 2026	clinicaltrials
NCT04920032	Study of ctDNA Guided Change in Tx for Refractory Minimal Residual Disease in Colon Adenocarcinomas	recruiting	Phase 1	22	University of California, IrvineOTHER	1	May 11, 2026	clinicaltrials
NCT03202940	A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC	active not recruiting	Phase 1 / Phase 2	16	Massachusetts General HospitalOTHER	1	May 8, 2026	clinicaltrials
NCT05694936	Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer	active not recruiting	Phase 2	38	Australasian Gastro-Intestinal Trials GroupNETWORK	1	May 8, 2026	clinicaltrials
NCT07466238	HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer	recruiting	N/A	40	Peking UniversityOTHER	1	May 8, 2026	clinicaltrials
NCT04439279	Testing Trametinib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol R)	active not recruiting	Phase 2	35	National Cancer Institute (NCI)NIH	1	May 7, 2026	clinicaltrials
NCT04439344	Testing Binimetinib as a Potential Targeted Treatment in Cancers With NRAS Genetic Changes (MATCH-Subprotocol Z1A)	active not recruiting	Phase 2	53	National Cancer Institute (NCI)NIH	1	May 7, 2026	clinicaltrials
NCT06761417	A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults	recruiting	Phase 2	49	Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER	1	May 7, 2026	clinicaltrials
NCT07570914	Hepatic Arterial Infusion of Liposomal Irinotecan Plus Oxaliplatin and Capecitabine as Adjuvant Therapy for Colorectal Cancer Liver Metastases	not yet recruiting	Phase 2	28	Tianjin Medical University Cancer Institute and HospitalOTHER	0	May 6, 2026	clinicaltrials
NCT07503756	JS212 Combination Therapies in Metastatic Colorectal Cancer	recruiting	Phase 2	80	Shanghai Junshi Bioscience Co., Ltd.OTHER	1	May 5, 2026	clinicaltrials
NCT05491811	Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation(EAGLE)	active not recruiting	Phase 2	47	Sun Yat-sen UniversityOTHER	1	May 4, 2026	clinicaltrials
NCT05195632	Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer(OCEANII)	active not recruiting	Phase 2	63	Pierre Fabre MedicamentINDUSTRY	2	May 1, 2026	clinicaltrials
NCT07562659	Randomized Controlled Study of Plasma ctDNA Methylation-Guided Adjuvant Chemotherapy in Stage I/Low-Risk Stage II Colorectal Cancer(CLEAR-01)	recruiting	Phase 2	80	Fudan UniversityOTHER	1	May 1, 2026	clinicaltrials
NCT07562711	Randomized Study of Plasma ctDNA Methylation to Guide Adjuvant Chemotherapy Decisions in High-Risk T3N0 Colorectal Cancer(CLEAR-02)	recruiting	Phase 2	340	Fudan UniversityOTHER	1	May 1, 2026	clinicaltrials
NCT03122717	Osimertinib and Gefitinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer	active not recruiting	Phase 1 / Phase 2	48	Dana-Farber Cancer InstituteOTHER	1	Apr 29, 2026	clinicaltrials
NCT03363217	Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.	active not recruiting	Phase 2	114	St. Justine's HospitalOTHER	1	Apr 24, 2026	clinicaltrials
NCT07020221	A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors	recruiting	Phase 1 / Phase 2	295	Verastem, Inc.INDUSTRY	2	Apr 22, 2026	clinicaltrials
NCT07543744	A Comparative Study of Pharmacokinetics, Safety, and Immunogenicity of RPH-030 and Vectibix® in Patients With Metastatic Colorectal Cancer With Wild-type RAS as First-line Therapy in Combination With FOLFIRI	recruiting	Phase 1	180	R-PharmINDUSTRY	1	Apr 22, 2026	clinicaltrials
NCT06280495	Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients	recruiting	Phase 2 / Phase 3	156	Sun Yat-sen UniversityOTHER	1	Apr 20, 2026	clinicaltrials
NCT07340164	Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy(TROY)	recruiting	Phase 2	116	Yonsei UniversityOTHER	1	Apr 20, 2026	clinicaltrials
NCT06544655	A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors	active not recruiting	Phase 1	213	Bristol-Myers SquibbINDUSTRY	3	Apr 17, 2026	clinicaltrials
NCT01187199	Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer	active not recruiting	Phase 1	278	M.D. Anderson Cancer CenterOTHER	1	Apr 16, 2026	clinicaltrials
NCT05026983	Binimetinib and Encorafenib for the Treatment of Metastatic Melanoma and Central Nervous System Metastases	recruiting	Phase 2	35	M.D. Anderson Cancer CenterOTHER	1	Apr 16, 2026	clinicaltrials
NCT07288034	Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial	recruiting	Phase 2	535	City of Hope Medical CenterOTHER	1	Apr 15, 2026	clinicaltrials

A study listed here tests a linked drug in a linked cancer; it does not necessarily select participants on this biomarker.

Approval rows flagged tumor-agnostic (4)

Associated cancers (24)

Drugs with predictive evidence (29)

Predictive evidence items (92)

Approvals mentioning the linked drugs (364)

Active trials (473)

Linked publications (85)